Mutations of ASXL1 gene in myeloproliferative neoplasms
N Carbuccia, A Murati, V Trouplin, M Brecqueville… - Leukemia, 2009 - nature.com
Leukemia, 2009•nature.com
1 Kyle RA, Vincent Rajkumar S. Treatment of multiple myeloma: an emphasis on new
developments. Ann Med 2006; 38: 111–115. 2 McConkey DJ, Zhu K. Mechanisms of
proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008; 11: 164–179.
3 Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy.
Leukemia 2002; 16: 433–443. 4 Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho
MN et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome …
developments. Ann Med 2006; 38: 111–115. 2 McConkey DJ, Zhu K. Mechanisms of
proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008; 11: 164–179.
3 Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy.
Leukemia 2002; 16: 433–443. 4 Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho
MN et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome …
1 Kyle RA, Vincent Rajkumar S. Treatment of multiple myeloma: an emphasis on new developments. Ann Med 2006; 38: 111–115. 2 McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008; 11: 164–179. 3 Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002; 16: 433–443. 4 Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383–6391. 5 Obeng EA, Carlson LM, Gutman DM, Harrington Jr WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907–4916.
nature.com